Citations

Clear

6274 citation(s) found for "To, Andrew".

Osteoporosis-related Vertebral Fragility Fractures
Robinson, William A. , Carlson, Bayard C. , Poppendeck, Heidi, Wanderman, Nathan , Bunta, Andrew D., Murphy, Sarah , Sietsema, Debra L. , Daffner, Scott D. , Watts, Nelson B. , Tosi, Laura L. , Anderson, Paul A. , Freedman, Brett A. , Wanderman, Nathan R, Edwards, Beatrice J.

Mayo Clinic

Spine | November 26, 2019 | Volume: 45 | Issue: 8 | Pages: E430-E438

10.1097/brs.0000000000003324 | PMID 31770343 Get It

Study Design. Retrospective cohort study of the Own the Bone database which is a fracture liaison service designed to improve recognition and treatment of osteoporosis. Objective. To use the Own the Bone (OTB) database to 1) examine the specific demographics of patients presenting with a low-energy clinical vertebral fracture (VFX) and 2) compare demographic and fracture-specific risk factors between patients with clinical VFX versus patients with nonvertebral low-energy fracture (NVFX). Summary of Background Data. Large database studies have described risk factors for developing VFX. It is well described that a history of previous VFX portends an increased risk of future VFX. Few studies have reported cohorts from a fracture liaison service such as the OTB initiative. Methods. 35,039 unique cases of fragility fracture occurred between 2009 and 2016 and were included in analysis. VFX accounted for 3395 (9.9%) of the presenting fractures at OTB enrollment. The demographics, lifestyle factors, medication use, and fracture-specific data for patients in the OTB registry with vertebral fractures were summarized and then statistically compared to those with nonvertebral fragility fractures. Results. The majority of VFX patients were Caucasian, postmenopausal women (74.4%). There was an increased likelihood of presenting with a vertebral fracture in patients who sustained a previous VFX after the age of 50, while patients who sustained a prior nonvertebral fracture (NVFX) were more likely to present with a subsequent NVFX. After controlling for patients with a history of fracture after the age of 50, VFX patients (vs. NVFX) were more likely to be age 70–79, class 1 obesity, with a history of taking anti-osteoporotic prescription medications. Conclusions. Multiple factors were associated with a significantly increased risk of VFX compared with NVFX. Understanding the risk factors unique to fragility VFX is a critical component for targeting “at-risk” patients and preventing future osteoporosis-related fractures and their consequences. Level of Evidence: 4
Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.
Tine, Brian Andrew Van, Hu, James , Schuetze, Scott M. , Attia, Steven , Priebat, Dennis A., Okuno, Scott H. , Riedel, Richard F. , Movva, Sujana , Baker, Laurence H. , Maki, Robert G. , Patel, Shreyaskumar , Tawbi, Hussein, Maki, Robert G , Riedel, Richard F , Burgess, Melissa , Roszik, Jason , D'Angelo, Sandra P , Davis, Lara E. , Reed, Damon R. , Reinke, Denise K. , Butterfield, Lisa Helene

Mayo Clinic

Journal of Clinical Oncology | November 26, 2019 | Volume: 35 | Issue: 7_suppl | Pages: 60-60

10.1200/jco.2017.35.7_suppl.60 Get It

60 Background: The activity of the anti-PD-1 antibody P in pts with advanced STS was evaluated in a prospective multicenter Phase II study conducted by the Sarcoma Alliance for Research through Collaboration (SARC). SARC028 enrolled 40 patients with advanced soft tissue sarcoma. Pembro had an ORR of 19% and PFS rate at 12 weeks of 55%, suggesting clinical activity. We investigated biomarkers of response to P. Methods: The primary endpoint was Objective Response Rate (ORR) by RECIST 1.1. Secondary endpoints included progression-free survival (PFS), overall survival, and biomarkers of response in blood and tumor. Pre- and on-treatment biopsies were required and obtained from over 90% and 72% of pts respectively. Serum was obtained from all pts at baseline and at multiple time points on therapy (pre-, week 8, and every 12 weeks). Sera were examined for candidate circulating biomarkers by Affymetrix Luminex platform array, including PD-L2. To determine whether there is a statistically significant difference between different conditions, we used Mann-Whitney and two-tailed t tests. Log-rank p-values in Kaplan-Meier survival analyses were calculated using the "survival" R package. Results: Forty pts with STS were enrolled into 4 cohorts (10 each) based on histological subtype including undifferentiated pleomorphic sarcoma (UPS), dedifferentiated liposarcoma (LPS), synovial sarcoma (SS), and leiomyosarcoma (LMS). 4 pts with UPS, 2 pts with LPS, and one pt with SS achieved a response. Six of seven responses were durable at the time of this analysis. Circulating levels at baseline or after therapy of PD-1, PD-L1, 4-1BB, IDO, BTLA, CTLA-4, LAG-3, and TIM-3 did not correlate with outcome. However, pre-treatment and week 8 PD-L2 levels correlated best with clinical outcome: high PD-L2 levels were associated with better PFS (p=0.019) in STS. Conclusions: P has clinical activity in specific histologic subtypes of STS, namely UPS and LPS. Pre-treatment circulating PD-L2 levels correlated with progression-free survival and is a novel and promising predictor of improved clinical outcome of PD-1 therapy in STS.
microRNA overexpression in slow transit constipation leads to reduced Na V 1.5 current and altered smooth muscle contractility
Mazzone, Amelia , Strege, Peter R. , Gibbons, Simon J. , Alcaino, Constanza , Joshi, Vikram , Haak, Andrew J. , Tschumperlin, Daniel J. , Bernard, Cheryl E., Chua, Heidi K, Graham, Rondell P. , Refaey, Mona El , Mohler, Peter J. , Hayashi, Yujiro , Ördög, Tamás , Du, Peng , Farrugia, Gianrico , Ordog, Tamas , Du, Peng , Farrugia, Gianrico , Beyder, Arthur , Gibbons, S J , Graham, Rondell P , Strege, Peter R , Mazzone, Amelia , Cima, Robert R. , Larson, David W. , Calder, Stefan , Beyder, Arthur , Joshi, Vikram

Mayo Clinic

Gut | November 22, 2019 | Volume: 69 | Issue: 5 | Pages: 868-876

10.1136/gutjnl-2019-318747 | PMID 31757880 Get It

Objective This study was designed to evaluate the roles of microRNAs (miRNAs) in slow transit constipation (STC). Design All human tissue samples were from the muscularis externa of the colon. Expression of 372 miRNAs was examined in a discovery cohort of four patients with STC versus three age/sex-matched controls by a quantitative PCR array. Upregulated miRNAs were examined by quantitative reverse transcription qPCR (RT-qPCR) in a validation cohort of seven patients with STC and age/sex-matched controls. The effect of a highly differentially expressed miRNA on a custom human smooth muscle cell line was examined in vitro by RT-qPCR, electrophysiology, traction force microscopy, and ex vivo by lentiviral transduction in rat muscularis externa organotypic cultures. Results The expression of 13 miRNAs was increased in STC samples. Of those miRNAs, four were predicted to target SCN5A , the gene that encodes the Na + channel Na V 1.5. The expression of SCN5A mRNA was decreased in STC samples. Let-7f significantly decreased Na + current density in vitro in human smooth muscle cells. In rat muscularis externa organotypic cultures, overexpression of let-7f resulted in reduced frequency and amplitude of contraction. Conclusions A small group of miRNAs is upregulated in STC, and many of these miRNAs target the SCN5A-encoded Na + channel Na V 1.5. Within this set, a novel Na V 1.5 regulator, let-7f, resulted in decreased Na V 1.5 expression, current density and reduced motility of GI smooth muscle. These results suggest Na V 1.5 and miRNAs as novel diagnostic and potential therapeutic targets in STC.
Meeting Report: The Dallas Consensus Conference on Liver Transplantation for Alcohol Associated Hepatitis
Asrani, Sumeet K. , Trotter, James F. , Lake, Jack, Bonagura, Anthony, Cameron, Andrew M. , DiMartini, Andrea F. , Martin, Paul , Mathurin, Philippe , Mellinger, Jessica L. , Rice, John P. , Shah, Vijay H. , Winder, Scott, Klintmalm, Göran B. , DiMartini, Andrea , Im, Gene , Shah, Vijay H , Terrault, Norah , Winder, Scott , Asrani, Sumeet K , Lake, Jack, Ahmed, Aijaz , Gonzalez, Stevan A , Martin, Paul, Terrault, Norah A. , Wall, Anji

Mayo Clinic

Liver Transplantation | November 19, 2019 | Volume: 26 | Issue: 1 | Pages: 127-140

10.1002/lt.25681 | PMID 31743578 Get It

Liver transplantation (LT) for alcohol associated hepatitis (AH) remains controversial. We convened a consensus conference to examine various aspects of LT for AH. The goal was not to unequivocally endorse LT for AH; instead, it was to propose recommendations for programs that perform or plan to perform LT for AH. Criteria were established to determine candidacy for LT in the setting of AH and included the following: (1) AH patients presenting for the first time with decompensated liver disease that are nonresponders to medical therapy without severe medical or psychiatric comorbidities; (2) a fixed period of abstinence prior to transplantation is not required; and (3) assessment with a multidisciplinary psychosocial team, including a social worker and an addiction specialist/mental health professional with addiction and transplantation expertise. Supporting factors included lack of repeated unsuccessful attempts at addiction rehabilitation, lack of other substance use/dependency, acceptance of diagnosis/insight with a commitment of the patient/family to sobriety, and formalized agreement to adhere to total alcohol abstinence and counseling. LT should be avoided in AH patients who are likely to spontaneously recover. Short‐term and longterm survival comparable to other indications for LT must be achieved. There should not be further disparity in LT either by indication, geography, or other sociodemographic factors. Treatment of alcohol‐use disorders should be incorporated into pre‐ and post‐LT care. The restrictive and focused evaluation process described in the initial LT experience for AH worldwide may not endure as this indication gains wider acceptance at more LT programs. Transparency in the selection process is crucial and requires the collection of objective data to assess outcomes and minimize center variation in listing. Oversight of program adherence is important to harmonize listing practices and outcomes.
Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripes
Staron, Andrew , Kataria, Yachana , Murray, David , Sloan, J. Mark , Sanchorawala, Vaishali , Murray, David L., Sanchorawala, Vaishali

Mayo Clinic

American Journal of Hematology | November 18, 2019 | Volume: 95 | Issue: 2 | Pages: No page available

10.1002/ajh.25685 | PMID 31736101 Get It

Intercontinental collaborative experience with abdominal, retroperitoneal and pelvic schwannomas
Group, Transatlantic Australasian Retroperitoneal Sarcoma Working, Barros, J Monteiro de, Hodson, James , Glasbey, James , Massey, Robert L., Rintoul-Hoad, O, Chetan, M , Desai, A , Gourevitch, David, Ford, Samuel , Hayes, Andrew , Lopez‐Aguiar, Alexandra G. , Johnson, Aileen C. , Swallow, Carol J. , Burtenshaw, Sally M., Weng, R, Purgin, B, Raut, Chandrajit P. , Fairweather, Mark , Novak, Marko , Reid, Fiona , Mullinax, John E. , Coevorden, Frits van , Houdt, Winan J. van , Haas, Rick L. , Boven, Hester van, Heeres, Birthe C. , van Houdt, Winan J , Group, Transatlantic Australasian Retroperitoneal Sarcoma Working, Massey, R, Almond, Max , Strauß, D. , Smith, Henry George , Cardona, Kenneth , Nessim, Carolyn , Gronchi, Alessandro , Fiore, M, Callegaro, Dario , Bagaria, Sanjay P. , Gyorki, David E. , González, Ricardo

Mayo Clinic

Journal of British Surgery | November 18, 2019 | Volume: 107 | Issue: 4 | Pages: 452-463

10.1002/bjs.11376 | PMID 31736066 Get It

Abstract Background Schwannomas are rare tumours that pose a significant management challenge in the abdomen, retroperitoneum and pelvis. No data are available to inform management strategy. Methods A collaborative international cohort study, across specialist sarcoma units, was conducted to include adults presenting between 2000 and 2017 with histopathologically confirmed schwannomas within the abdomen, retroperitoneum or pelvis. Results Of 485 patients across 12 centres, 38 (7·8 per cent) were discharged without follow-up, 199 (41·0 per cent) underwent early resection and 248 (51·1 per cent) had radiological monitoring. Of these 248 patients, 96 (38·7 per cent) eventually had surgery, giving an overall resection rate of 60·8 per cent (295 of 485). At baseline, median tumour volume was 90·1 (i.q.r. 26·5–262·0) cm3. The estimated growth rate was 10·5 (95 per cent c.i. 9·4 to 11·6) per cent per year, and was consistent in the short term (within 2 years of diagnosis) and long term (beyond 2 years) (ρ = 0·405, P = 0·021). A decision to operate was more common in symptomatic patients (P < 0·001) and for rapidly growing tumours (growth rate more than 20 per cent per year) (P = 0·025). R0/R1 resection was achieved in 91·6 per cent of patients (263 of 287). Kaplan–Meier long-term recurrence rates after R0/R1 resection were 2·3 and 6·7 per cent at 3 and 5 years respectively. Conclusion Specific recommendations include: indications for early surgery, prediction of growth from radiological monitoring, promotion of selective submacroscopic resection and cessation of postoperative imaging surveillance.
Blood Management Strategies to Reduce Transfusions after Elective Lower-Extremity Joint Arthroplasty Surgeries: One Tertiary Care Hospital's Early Experience with an Alternative Payment Model - a Total Joint 'Bundle
Dahiya, Saurabh , Andrzejewski, Chester , Krushell, Robert J., Lehman, Andrew , Greenbaum, Jordan , Ehresman, Alice, McGirr, Joan, Mahoney, Kathleen M. , Cloutier, Darlene, Kansagra, Ankit , VISINTAINER, PAUL F. , Mahoney, Kathleen, Stefan, Mihaela S.

Mayo Clinic

Blood | November 17, 2019 | Volume: 128 | Issue: 22 | Pages: 3854-3854

10.1182/blood.v128.22.3854.3854 Get It

Abstract Background and objective: Blood loss associated with total lower-extremity joint arthroplasty (TJA) often results in postoperative anemia and need for red blood cell transfusions (RBCT). We report the results of a quality improvement initiative to improve blood management and decrease transfusions in patients undergoing TJA in one tertiary hospital. Methods: Pre and post analysis after the implementation of a multifaceted intervention which included preoperative assessment for anemia, use of tranexamic acid, discouragement of autologous pre-operative blood collection and institution of more restrictive RBCT protocols. The results were stratified into three periods: I - pre-interventional (01/01/2013 -09/30/2013); II - peri-interventional (10/01/2013 -04/30/2014); and III - post-interventional (05/01/2014 -12/31/2014). We used fractional logistic regression with robust standard errors and regression modeling was configured using a segmented, or "piecewise", approach in which slope coefficients in each period were estimated. Results: During the study period 2511 patients underwent surgery. Compared with the pre-intervention period, the total number of RBC units transfused decreased from a total of 587 in the pre- to 107 in the post-intervention period (81.8% decrease). The percentage of patients receiving transfusion declined from 36.7% in pre-implementation period to 8.8% to post-intervention period. Depending upon the costing methodology used, annualized savings in RBC expenditure between time period 1 and 3 ranged from a low of $108,000 using the acquisition cost per unit (~$225/unit) to $480,000 when using activity based costing (~$1000/unit). Mean length of stay (days) and 30-day readmission rates remained stable during the study period. Conclusions: A multidisciplinary approach with proactive involvement of all the interested parties can be successful and sustainable in reducing RBCT and its associated costs, in patients undergoing TJA. Disclosures No relevant conflicts of interest to declare.
Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Crooks, Pauline, Lamy, Thierry , Ansell, Stephen M. , Roussel, Mikaël , Ghesquières, Hervé , Fest, Thierry , Cerhan, James R. , Gandhi, Maher K. , Azzaoui, Imane , Maurer, Matthew J. , Milpied, Noel Jean , Hertzberg, Mark , Slager, Susan L. , Feldman, Andrew L. , Habermann, Thomas M. , Witzig, Thomas E. , Link, Brian K. , Rossille, Delphine

Mayo Clinic

Blood | November 17, 2019 | Volume: 124 | Issue: 21 | Pages: 2998-2998

10.1182/blood.v124.21.2998.2998 Get It

Abstract Background. Recent clinical trials based on immunotherapies targeting the PD-1/PD-L1 pathway have shown striking durable responses in a subset of patients with solid cancers. The Programmed death 1 (PD-1) protein is a key immune checkpoint inhibitor expressed by activated T cells. Its ligand, PD-L1, was reported highly expressed by tumor cells in some diffuse large B-cell lymphomas (DLBCL) of non-Germinal Center phenotype. We recently reported on the French multicenter GOELAMS075 trial that pre-treatment soluble PD-L1 (sPD-L1) in plasma was elevated in DLBCL patients compared to controls, and that elevated sPD-L1 was associated with inferior overall survival (OS), independent of the International Prognostic Index (IPI) and other clinical factors (Rossille et al., Leukemia 2014). Here, we replicate and extend these findings in two independent studies from Australia and the US. Methods. The protein expression of sPD-L1 was evaluated using a commercial ELISA kit. The French discovery cohort consisted of 288 adults with newly diagnosed aggressive DLBCL, age 18 to 60 years, and treated with R-CHOP or high dose chemotherapy plus rituximab followed by autologous stem cell support (clinicaltrials.gov: NCT00561379); there were also 60 controls. The Australian study consisted of 51 DLBCL patients age 18 to 71 years, all stages, treated with R-CHOP14, along with 57 controls. The US study was an observational cohort from the Iowa/Mayo Lymphoma SPORE and consisted of 225 DLBCLs, age 19 to 92 years, all stages, treated with immunochemotherapy, along with 98 controls. Plasma samples were collected pre-treatment using EDTA tubes for the Australian and the US cohorts, BDª P100 tubes for the French cohort. sPD-L1 expression was measured in Rennes, France (French & US samples) and in Brisbane, Australia (Australian samples).The Kaplan-Meier method and Cox regression were used to model the association of sPD-L1 with OS. The 95th percentile of the sPD-L1 levels in each matched control group was used as the cutoff point to define elevated sPD-L1 levels. Results. Replicating the French findings, sPD-L1 levels were significantly higher for DLBCL patients compared to controls in both the US (P<0.0001) and Australian (P<0.0001) studies (Figure 1). The odds ratios for elevated sPD-L1 among patients compared to controls were 10.7 (95% CI 3.3-22.0), 8.9 (95% CI 3.1-25.3) and 12.6 (95% CI 2.7-28.0) for the French, US and Australian studies, respectively. In the French cohort, elevated sPD-L1 levels were associated with inferior OS (Hazard Ratio (HR)=2.05; 95% CI 1.18-3.57), and this was replicated in the US cohort (HR=1.71; 95% CI 0.97-3.01) (Figure 2). Due to the similarity of the results, we next pooled the French and US cohorts to increase power for multivariate and subset analyses. The median age at diagnosis of the 513 patients was 54 years; 29% were more than 60 years old; 69% of the patients had stage III-IV disease; 56% were IPI intermediate-risk and 9% were IPI high-risk patients. The median follow-up was 48 months (range, 0.5-126) overall, and 66 months for the patients still alive; there were 102 deaths. Using a cutpoint of 1729 pg/mL from the combined studies, patients with elevated sPD-L1 had inferior OS compared to patients without elevated sPD-L1, with 3-year OS rates estimated at 78% (95% CI 71.8-84.9) vs. 87.8% (95%CI 84.5-91.4) (P<0.01). In multivariate analysis, elevated sPD-L1 (HR=1.75; 95%CI 1.16-2.64), age (HR=1.03; 95%CI 1.02-1.05), high-risk IPI score (HR=3.71; 95%CI 1.91-7.21) and ALC ² 1 G/L (HR=2.19; 95%CI 1.44-3.33) were all significant at P<0.01. In analyses stratified by IPI, the 3-year OS rates among high-risk patients (IPI 4-5) was 40.9% (95% CI 23.6-71.0) for elevated sPD-L1 vs. 82.1% (95% CI 69.1-97.6) for not elevated sPD-L1 (P<0.01). There was no association of sPD-L1 with 3-year OS among low risk (IPI 0-1) or intermediate-risk (IPI 2-3) patients. Conclusion. We confirmed that sPD-L1 levels are higher in pre-treatment plasma samples of newly diagnosed DLBCL patients compared to controls, and that elevated levels of sPD-L1 are associated with inferior OS in DLBCL patients treated with immunochemotherapy, and this is independent of IPI and other clinical factors. Among high risk patients, we identified a subgroup with less than 50% survival. Figure 1 Figure 1. Figure 2 Figure 2. Disclosures No relevant conflicts of interest to declare.
No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era
Tracy, Sean , Perepu, Usha , Ansell, Stephen M. , Thompson, Carrie A. , Allmer, Cristine, Habermann, Thomas M. , Feldman, Andrew L. , Maurer, Matthew J. , Doǧan, Ahmet , Syrbu, Sergei , Weiner, George J. , Slager, Susan L. , Witzig, Thomas E. , Cerhan, James R. , Link, Brian K.

Mayo Clinic

Blood | November 17, 2019 | Volume: 128 | Issue: 22 | Pages: 107-107

10.1182/blood.v128.22.107.107 Get It

Abstract Background: EBV+ DLBCL not otherwise specified (EBV+ DLBCL NOS) is defined by the 2016 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues as EBV+ DLBCL in patients without a history of known immunosuppression. Among Asian patients, adverse outcomes have been associated with EBV+ vs EBV- DLBCL, and circulating EBV has been found in the majority of patients. Outcome studies of unselected North American patients are few and non-confirmatory. No formal assessment of immunosuppression status has been incorporated into these analyses, leading to the variable inclusion of patients with a history of immunocompromised states. We sought to determine the prevalence, presenting clinical and pathology characteristics, and outcomes of DLBCL by EBV and immunosuppression status in an unselected prospective cohort study of North American patients. Methods: From 2002-2012, we enrolled consecutive, newly diagnosed patients with lymphoma who were ≥ 18 years and HIV negative into the Molecular Epidemiology Resource (MER). Clinical, laboratory, and treatment data were abstracted from medical records. All DLBCL patients with available tissue microarrays (TMAs), excluding primary mediastinal DLBCL and post-transplant lymphoproliferative disorders, were included. Medical records were reviewed using a standard protocol to classify patients as immunocompromised based on a documented history of primary immunodeficiency or iatrogenic immunosuppression. DLBCL cell of origin was classified as germinal center (GCB) vs non-GCB using the Hans algorithm. CD30 was determined using immunohistochemistry; positivity cutoff was 20% of neoplastic cells. EBV testing was performed by in-situ hybridization for EBV encoded small RNAs (EBERs), and scored by an expert hematopathologist. Event free survival (EFS) was defined as time from diagnosis until recurrence, retreatment, or death due to any cause. Associations with EFS and Overall Survival (OS) were obtained using the methods of Kaplan-Meier (KM). Hazard Ratios (HRs) and 95% confidence intervals (CIs) were estimated from Cox regression models. Results: 1,100 patients with DLBCL were enrolled into the MER; 362 had TMAs available for this analysis. Median age was 63 years (range 20-89) and 59% were male. 89.5% of patients were treated with immunochemotherapy. 16 cases (4.4%) were EBV+, and 39 cases (10.8%) were considered immunocompromised. EBV positivity was more common in immunocompromised vs immunocompetent patients, with a trend towards significance (10.3% vs 3.7%; P = 0.08). The non-GCB subtype was more frequent in EBV+ vs EBV- DLBCL (62.5% vs 34.1%; P < 0.01), but similar between immunocompromised vs immunocompetent patients (48.7% vs 33.7%; P = 0.10). CD30 positivity was also more frequent in EBV+ vs. EBV- DLBCL (25.0% vs 8.1%; P < 0.01), but similar between immunocompromised vs immunocompetent patients (12.8% vs 8.4%, respectively; P = 0.45). With a median follow-up of 59 months (range 0.7-155.2) there were 151 events and 119 deaths. KM curves by EBV and immunosuppression status are shown in the figure. There was no association of EBV positivity with EFS (HR = 0.76; 95% CI 0.34-1.72) or OS (HR = 0.99; 95% CI 0.43-2.25). A history of immunosuppression was not associated with EFS (HR = 1.17; 95% CI 0.72-1.89) or OS (HR = 1.02; 95% CI 0.58-1.78). In the subset of immunocompetent patients, there was no association of EBV positivity with EFS (HR = 0.54; 95% CI 0.17-1.70) or OS (HR = 0.71; 95% CI 0.23-2.25). Similar results were obtained after adjustment for the International Prognostic Index. Circulating viral DNA was detected in 2/5 EBV+ and 4/49 EBV- DLBCL patients. Conclusions: The prevalence of EBV+ DLBCL NOS is <5% among patients in a large North American cohort, similar to other western populations. There was no evidence of an association of EBV or immunosuppression status with EFS or OS, with low power for detecting associations with EBV. Circulating viral DNA was infrequent among either EBV+ or EBV- DLBCL patients. While immunosuppression has been previously shown to be a risk factor for DLBCL, it was not found to be associated with EFS or OS. Overall, these results suggest divergent outcomes among EBV+ DLBCL patients between western and non-western populations, underscoring differences in host factors or circulating viral strains. Disclosures Ansell: BMS, Seattle Genetics, Merck, Celldex and Affimed: Research Funding.
Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis
Moyo, Tamara K. , Sochacki, Andrew , Ayers, Gregory D. , Byrne, Michael , Harrison, Jill Lindsey , Berry, Lynne D. , Dudley, Channing V. , Severs, Rachel , Dugger, Laura , Miskin, Hari P., Cavers, Amy, Sportelli, Peter, Michaelis, Laura C. , Strickland, Stephen Anthony , Mohan, Sanjay , Harrison, Jill, Mesa, Ruben A. , Savona, Michael R.

Mayo Clinic

Blood | November 17, 2019 | Volume: 128 | Issue: 22 | Pages: 1125-1125

10.1182/blood.v128.22.1125.1125 Get It

Abstract Background: Therapies for myelofibrosis (MF) are limited and most are palliative. The JAK1/2 inhibitor ruxolitinib reduces spleen size and MF-related symptoms and improves survival, but can be limited by dose-dependent anemia and thrombocytopenia. Moreover, nearly half of ruxolitinib responders relapse within 5 years. PI3Kd is highly expressed in MF patient samples, independent of ruxolitinib pre-exposure. In JAK2-mutated cell lines, inhibition of PI3K/AKT signaling reduced proliferation and clonogenic potential. The once daily, next generation PI3Kd inhibitor TGR-1202 inhibited PI3K/AKT signaling and led to apoptosis in leukemia and lymphoma cell lines and was well-tolerated in clinical studies, with a toxicity profile distinct from that of ruxolitinib and other PI3Kd inhibitors. We hypothesized that adding TGR-1202 to ruxolitinib could resensitize or augment the response of MF patients with lost or suboptimal response to single-agent ruxolitinib. Objective: To assess safety of TGR-1202 in combination with ruxolitinib in MF patients Secondary Objectives: Hematologic response, symptom assessment Methods: MF patients who had sub-optimal responses to ruxolitinib continued their highest tolerated dose of ruxolitinib without change for ≥ 8 weeks, and were assigned to escalating doses of TGR-1202 in a standard 3+3 algorithm. Adverse events (AEs) were graded by NCI-CTCAE v4.03. Efficacy was assessed according to IWG-MRT consensus response criteria. Symptoms were assessed by the MPN symptom assessment form total symptom score (TSS). All patients received Pneumocystis pneumonia prophylaxis after cycle 1. Results: Eleven MF patients were enrolled and received 400 mg (n=3), 800 mg (n=6), or 600 mg TGR-1202 (n=2) daily. Nine were evaluable for response. Median age was 66y, 73% were male. All had ECOG PS 0-1. Five patients had mutations in JAK2, 4 in CALR, and 3 in MPL; these were mutually exclusive with exception of 1 patient with CALR and MPL mutations (Table 1). Median number of cycles of TGR-1202 + ruxolitinib treatment was 5 (1-13). Grade 2 anemia was the most common AE (Table 2). Two patients had asymptomatic Grade 3 elevations in amylase and lipase that persisted after drug was held, meeting criteria for dose limiting toxicities (DLTs) in 2 separate cohorts (TGR-1202 800mg+ruxolitinib 15mg BID and TGR-1202 800mg+ruxolitinib 10mg BID). Both patients had peak plasma TGR-1202 concentrations 1.5-2x higher than the other patients receiving 800mg TGR-1202, although steady-state levels were equivalent. The maximum tolerated dose (MTD) of TGR-1202 in combination with ruxolitinib was not established. Two patients went off-study due to AEs, and 3 due to progressive disease. One of 9 evaluable patients achieved complete remission and 7 had stable disease. Seven of the 9 evaluable patients had improvement in hematologic parameters and 8 had reduced MF symptoms with a median 33% decrease in TSS (Fig. 1). Conclusions: TGR-1202 + ruxolitinib was well-tolerated. Pharmacokinetic data were consistent with single-agent TGR-1202 (unpublished data), indicating that ruxolitinib does not alter absorption or metabolism of TGR-1202. Grade 3 elevations in amylase and lipase were considered DLTs, per protocol. Although the clinical significance of these asymptomatic laboratory findings is not clear, the protocol was amended to further assay these labs and to exclude concomitant medications with the potential to increase amylase/lipase. Importantly, no grade ≥3 hepatotoxicity, colitis, or thrombocytopenia was seen and no MTD was found. Although only one patient achieved CR, 89% demonstrated clinical benefit with the addition of TGR-1202 to ruxolitinib, supporting further exploration of this combination. Disclosures Strickland: Alexion Pharmaceuticals: Consultancy; Ambit: Consultancy; Baxalta: Consultancy; Boehringer Ingelheim: Consultancy, Research Funding; CTI Biopharma: Consultancy; Daiichi Sankyo: Consultancy; Sunesis Pharmaceuticals: Consultancy, Research Funding; Abbvie: Research Funding; Astellas Pharma: Research Funding; Celator: Research Funding; Cyclacel: Research Funding; GlaxoSmithKline: Research Funding; Karyopharm Therapeutica: Research Funding; Sanofi: Research Funding. Miskin:TG Therapeutics, Inc: Employment, Equity Ownership. Cavers:TG Therapeutics: Employment, Equity Ownership. Sportelli:TG Therapeutics, Inc.: Employment, Equity Ownership. Michaelis:Pfizer: Equity Ownership; Cellgene Corporation: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte Corporation: Consultancy, Honoraria. Mesa:CTI: Research Funding; Promedior: Research Funding; Celgene: Research Funding; Gilead: Research Funding; Incyte: Research Funding; Galena: Consultancy; Ariad: Consultancy; Novartis: Consultancy. Savona:Amgen Inc.: Membership on an entity's Board of Directors or advisory committees; TG Therapeutics: Research Funding; Ariad: Membership on an entity's Board of Directors or advisory committees; Takeda: Research Funding; Sunesis: Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees.